Bloomberg |
Roche's New Drugs May Protect its Old Ones
Bloomberg Roche Holding AG's blockbuster cancer drugs face a huge impending sales decline in the next few years. Its investors aren't worried. The company's ADRs spiked as much 6.8 percent on Thursday, in response to positive trial data for a combination of ... Roche's Perjeta chalks up needed win in Herceptin combo trial, but questions remain Roche's (RHHBY) Genentech Says Phase III APHINITY Study Met Primary Endpoint in Breast Cancer Study Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win |
from Health - Google News http://ift.tt/2lZJ9jd
EmoticonEmoticon